Erschienen in:
01.04.2015 | Original Article
Additional androgen deprivation makes the difference
Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy
verfasst von:
Jonas Schiffmann, MD, Hans Lesmana, Pierre Tennstedt, Burkhard Beyer, Katharina Boehm, Volker Platz, Derya Tilki, Georg Salomon, Cordula Petersen, Andreas Krüll, Markus Graefen, Rudolf Schwarz
Erschienen in:
Strahlentherapie und Onkologie
|
Ausgabe 4/2015
Einloggen, um Zugang zu erhalten
Abstract
Background
The role of additional androgen deprivation therapy (ADT) in prostate cancer (PCa) patients treated with combined HDR brachytherapy (HDR-BT) and external beam radiotherapy (EBRT) is still unknown.
Patients and methods
Consecutive PCa patients classified as D’Amico intermediate and high-risk who underwent HDR-BT and EBRT treatment ± ADT at our institution between January 1999 and February 2009 were assessed. Multivariable Cox regression models predicting biochemical recurrence (BCR) were performed. BCR-free survival was assessed with Kaplan–Meier analyses.
Results
Overall, 392 patients were assessable. Of these, 221 (56.4 %) underwent trimodality (HDR-BT and EBRT and ADT) and 171 (43.6 %) bimodality (HDR-BT and EBRT) treatment. Additional ADT administration reduced the risk of BCR (HR: 0.4, 95 % CI: 0.3–0.7, p < 0.001). D’Amico high-risk patients had superior BCR-free survival when additional ADT was administered (log-rank p < 0.001). No significant difference for BCR-free survival was recorded when additional ADT was administered to D’Amico intermediate-risk patients (log-rank p = 0.2).
Conclusions
Additional ADT administration improves biochemical control in D’Amico high-risk patients when HDR-BT and EBRT are combined. Physicians should consider the oncological benefit of ADT administration for these patients during the decision-making process.